ANVS - NYSE

Annovis Bio, Inc.

Annovis Bio, Inc.

ANVSยทNYSE

$2.60

+0.78%
HealthcareBiotechnology

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$51.15M
EPS-1.4000
P/E Ratio-2.46
Earnings Date05/11/2026
Annovis Bio, Inc.

Annovis Bio, Inc. Fair Value Envelope

ANVS ยท NYSE

Our analysis suggests that ANVS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.6, this represents a potential HIDDEN relative to our calculated worth for Annovis Bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $2.6

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$78.9B
+ Cash & Equivalents$19.5B
Firm Value-$59.4B
- Debt$0
Equity Value-$59.4B
/ Shares Outstanding19,673,615B
DCF Value-$3.0K
OVERVALUED BY 116159%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$21.3B
-$17.6B
-$14.6B
-$12.2B
-$10.1B
-$8.4B
-$6.9B
-$5.8B
-$4.8B
-$4.0B
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$21.3B
-$17.6B
-$14.6B
-$12.2B
-$10.1B
-$8.4B
-$6.9B
-$5.8B
-$4.8B
-$4.0B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$19.7B
-$15.1B
-$11.6B
-$8.9B
-$6.9B
-$5.3B
-$4.1B
-$3.1B
-$2.4B
-$1.8B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ANVS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.